Free shipping on all orders over $ 500

GSK2636771

Cat. No. M2050
GSK2636771 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 54  USD60 In stock
5mg USD 81  USD90 In stock
10mg USD 153  USD170 In stock
50mg USD 369  USD410 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

GSK2636771 is a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kβ) for the treatment of PTEN deficient tumors. GSK2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK2636771 decreases phosphorylated protein kinase Akt (Ser473) levels in these xenograft models. GSK2636771 (100 mg/kg) do not increase glucose/insulin levels in mice. GSK2636771 is currently in Phase I/II trials.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Cell (2015). Figure 3. GSK2636771 (Abmole)
Method Tumor growth assay
Cell Lines
Concentrations 30mg/kg per oral gavage daily
Incubation Time 21 days
Results Both BYL719 and GSK2636771, a structurally unrelated p110b inhibitor currently in clinical trials, slowed tumor growth but only the combination induced tumor shrinkage.
Source Cancer Cell (2015). Figure 3.GSK2636771 (Abmole)
Method Immunoblotting
Cell Lines BT-474, SKBR3 cell
Concentrations 1µM
Incubation Time 24 h
Results This led to the loss of p110b recruitment and the block of the rebound of AKT activation observed 24 hr after treatment with BYL719 alone.
Protocol
Cell Experiment
Cell lines EEC cell lines
Preparation method Cells were plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/ well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24h, cells were treated with serial dilutions (100pM to 10μM) of PI3K and MAPK pathway inhibitors (Supplementary Methods, Supplementary Table 3). Cell viability was assessed after 72h of treatment by incubation with CellTiter Blue (Promega, Southampton, UK) for 1.5h.
Concentrations 100pM to 10μM
Incubation time 72h
Animal Experiment
Animal models 6- to 8-week-old female athymic nude mice BT474 tumor model
Formulation GSK2636771 was dissolved on 0.5% metilcellulose and 0.2% Tween 80.
Dosages 30mg/kg daily
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 433.42
Formula C22H22F3N3O3
CAS Number 1372540-25-4
Purity >99%
Solubility DMSO 26 mg/mL
Storage at -20°C
Related PI3K Products
Linperlisib (YY-20394)

Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ inhibitor.

Leniolisib

Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor with IC50 of 11 nM.

Seletalisib

Seletalisib (UCB5857) is a potent and selective PI3Kδ inhibitor, with IC50 of 12 nM.

Glaucocalyxin A

Glaucocalyxin A is an ent-kauranoid diterpene from Rabdosia japonica var.

BAY1082439

BAY1082439 is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: GSK2636771 supplier, PI3K, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.